Most Read

PCI will add expanded Biotech clinical and commercial packaging and release testing capability at its Center of Excellence in Philadelphia, as well as expanded Cold Chain capacity at

CytoReason will receive from Pfizer payments potentially equaling up to low double digit millions of US$ for technology access fees, research support and certain success-based payments. CytoReason’s proprietary

The collaboration will combine Genentech’s global cancer immunotherapy research and development leadership with Adaptive’s proprietary T-cell receptor (TCR) discovery and immune profiling platform (TruTCR) to accelerate a transformational

The collaboration, established in October 2017, aims to discover and develop novel GalXC RNAi therapeutics for the treatment of chronic liver diseases, with an initial focus on nonalcoholic

This collaboration will leverage Click’s demonstrated ability to discover and validate a software application and deploy it commercially, with Otsuka’s expertise in developing approved prescription therapies for patients

Deciphera president and CEO Dr Michael Taylor said: “We are extremely pleased with the recent progress made on our rebastinib program, including today’s announcement that we have initiated

The settlement with Mylan is the third patent infringement settlement the companies have reached with respect to LINZESS. Pursuant to the terms of the settlement, Ironwood and Allergan

Nuvo’s president and CEO Jesse Ledger said: “The close of this transaction positions Nuvo as one of the premier specialty pharmaceutical companies in Canada. “Nuvo is now truly

Andexxa received both U.S. Orphan Drug and FDA Breakthrough Therapy designations and was initially approved on May 3, 2018 under the FDA’s Accelerated Approval pathway. It is the